TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that the first commercial benign prostatic hyperplasia ("BPH") treatment utilizing the TULSA-PRO system's new TULSA-AI Volume Reduction Module was successfully conducted yesterday by Naveen Kella, M.D., Founder of ...

CARLSBAD, CALIFORNIA, June 10, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a pioneer in innovative spinal solutions, proudly announces that its proprietary SiLO™ Sacroiliac (SI) Joint Fusion System has been successfully used in over 2,500 procedures across the United States. This major milestone underscores the company’s accelerating growth and increasing adoption of its minimally invasive technology by surgeons nationwide. Aurora’s SiLO™ p ...

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. alleging securities fraud affecting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Treace Medical Concepts, Inc. made false statements regarding the impact of competition on the demand for its primary product, the 3D bunion correction system, "Lapiplasty" [2]. - It is alleged that due to competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2]. - The defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Lisa Bedell Clive +44 207 676 7256 lisa.clive@bernsteinsg.com Delphine Le Louet +33 1 42 13 92 93 delphine.le-louet@bernsteinsg.com 6 June 2025 European Consumer Medical Technologies Global Ophthalmology: Laser-focused on procedure growth, mix, and China: A primer on the Refractive market Susannah Ludwig +41 582 723 127 susannah.ludwig@bernsteinsg.com Lee Hambright +1 917 344 8429 lee.hambright@bernsteinsg.com Richard Hombach +44 207 762 1858 richard.hombach@bernsteinsg.com Deeksha Pandey +1 917 344 8447 de ...

Core Insights - Anteris Technologies Global Corp. has appointed Mr. David Roberts and Mr. Gregory Moss to its Board of Directors, enhancing its leadership team as it prepares for the upcoming global pivotal clinical trial for its DurAVRTHV product [1][2][4] - The company is transitioning to a new growth phase following its NASDAQ listing in Q4 2024 and aims for U.S. and EMA licensure of the DurAVRTHV for patients with aortic stenosis [2][4] Leadership Appointments - Mr. David Roberts has extensive experience in the healthcare sector, currently serving as President of LeMaitre Vascular, Inc. since 2007, and has held various leadership roles since joining the company in 1997 [2][3] - Mr. Gregory Moss brings a strong legal and compliance background, having served as Chief Business and Legal Officer at Evommune, Inc., and previously held senior roles at Kadmon, culminating in a $1.9 billion acquisition in 2021 [3] Product Overview - Anteris' lead product, the DurAVR Transcatheter Heart Valve (THV), is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate normal aortic blood flow [6] - The DurAVR THV is made from Anteris' patented ADAPT tissue technology, which has been clinically used for over 10 years and distributed to over 55,000 patients worldwide [6]

AtriCure (ATRC) FY Conference Summary Company Overview - **Company**: AtriCure (ATRC) - **Date of Conference**: June 09, 2025 - **Key Speaker**: Angie Weirich, Chief Financial Officer Key Points and Arguments Industry and Market Dynamics - AtriCure operates in the cardiac surgery and electrophysiology markets, focusing on atrial fibrillation (AFib) treatment and pain management solutions [3][4][19] - The company emphasizes the importance of preventative care in cardiac surgery, highlighting the LEAPS clinical trial and BOXNOAF trial as significant initiatives [3][4][22] Product Portfolio and Innovations - AtriCure's product portfolio includes PFA catheters and the AtriClip device, which are critical in the treatment of AFib and appendage management [4][20] - The company launched the AtriClip Flex Mini and Cryosphere Max probes, contributing to a 14% overall growth in the first quarter [39][28] - AtriCure is focused on expanding its appendage management franchise, with a new generation of AtriClip devices that are smaller and less invasive [20][21] Financial Performance and Growth Projections - AtriCure projects a top-line growth of 11% to 13% for the year, with a strong start at 14% [37][39] - The company is committed to improving profitability alongside double-digit revenue growth, despite facing challenges in the minimally invasive business segment [5][12][38] - The international business is growing rapidly but poses a margin headwind, with potential impacts of 10 to 40 points on margin depending on the country [49][50] Competitive Landscape - AtriCure faces competition from other less invasive treatments, particularly in the PFA catheter space, which has led to distractions for electrophysiologists (EPs) [6][13][40] - The CONVERGE clinical trial is positioned as a durable option for long-standing persistent AFib patients, despite initial challenges in adoption post-launch [10][12][14] Strategic Focus and Future Outlook - The company is prioritizing resource allocation towards its appendage management and pain management segments, while maintaining a cautious approach to the CONVERGE product line [24][28] - AtriCure is exploring new markets, including below-the-knee amputations, with the Cryo XT device set to launch later this year [29][30] - The long-term revenue target is set at $1 billion by 2030, with a focus on accelerating growth through clinical trials and market expansion [69][70] Operational Efficiency and Cost Management - AtriCure is focused on leveraging SG&A expenses and improving gross margins through new product launches and operational efficiencies [58][60] - The company has made significant investments in R&D, particularly in the LEAPS clinical trial, which is expected to yield long-term benefits [61][73] Capital Allocation and M&A Strategy - AtriCure is currently focused on organic growth opportunities rather than acquisitions, emphasizing the importance of maintaining profitability [81][82] - The company is cautious about pursuing M&A that could negatively impact its bottom line trajectory [82] Additional Important Insights - The company is seeing an increase in new accounts despite the competitive pressures from PFA technology [17][24] - AtriCure's approach to training and education for healthcare practitioners has evolved, focusing on impactful methods to enhance customer engagement [62][63] - The management remains optimistic about the future, aiming to continue expanding its addressable market and driving revenue growth [84]

Becton, Dickinson and Company (NYSE:BDX) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Call Participants Robert Justin Marcus - JPMorgan Chase & Co, Research Division Unidentified Analyst Yes. One additional disclosure that we needed. So the session is not open to the press. There you go. All right. So I want to thank Tom Polen, Chairman and Chief Executive Officer of Becton, Dickinson. I appreciate ...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=151935&fr ...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI). Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=151932&from=3 ...

Company Overview - Sharps Technology, Inc. is an innovative medical device and pharmaceutical packaging company that offers patented smart safety syringe products to the healthcare industry [6] - The company focuses on ultra-low waste capabilities and incorporates both passive and active safety features in its syringe technologies [6] - Sharps has a manufacturing facility in Hungary that has undergone significant upgrades to support high-volume production [2][6] Recent Developments - Sharps has commenced shipments under three customer orders tied to previously announced purchase agreements, marking its first commercial deliveries and transition to revenue-generating operations [2] - The company will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET, providing an opportunity for investors to gain insights into its operations and future prospects [1][8] Investor Engagement - The Investor Summit is tailored for investors focused on small- and micro-cap stocks, offering insights from management teams of emerging companies [3][4] - Registration for the Investor Summit is available for free, allowing investors to participate and learn more about Sharps and other companies [5]